Gene editing company Intellia Therapeutics is broadening its research efforts by targeting diseases of the eye through a new deal announced Wednesday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,